Recoveries: 350,549
Actions to slow the spread of Covid-19:
10 December: Saudi Food & Drug Authority (SFDA) says it has approved the registration of Pfizer-BioNTech s Covid-19 vaccine in the kingdom. The approval was based on the data provided by Pfizer on 24 November.
7 December: The first group of Umrah performers from outside the country have arrived in Madina, including 135 visitors from Indonesia. The visitors have been quarantined for three days and their entry will be managed using the Eatmarna Umrah mobile app.
6 December: The Assistant Health Minister and official spokesperson of the Saudi Health Ministry, Muhammad al-Abdulaali, has stated that Saudi Arabia has signed very important contracts with companies developing the coronavirus vaccine , adding that the registration mechanism for taking the vaccine will be announced soon.
Get the best of the FT with
editor-written newsletters on 6 key global themes: trends in responsible investing, mergers & acquisitions, tech in Asia, energy, global trade and the business of sports.Select
Get access to these 6 newsletters and any article featured within them:
Moral Money – Your trusted source for news and analysis about socially responsible business, sustainable finance and ESG trends. Twice Weekly.
Due Diligence – The curated, must-read content on corporate finance, mergers & acquisitions, and private equity with scoops and news you can t find elsewhere.
#techAsia – The essential newsletter offering deep and exclusive insight into the billions being made and lost in Asia s technology sectors. Brought to you weekly from the FT and Nikkei.
[Photo/Agencies]
MANAMA - Bahrain s health regulator on Sunday announced it has officially approved the registration of a COVID-19 vaccine developed by the China National Pharmaceutical Group, or Sinopharm, according to Bahrain News Agency.
The National Health Regulatory Authority made the decision to approve and use the vaccine after thorough review and evaluation of the clinical trials data, the report said. Results from Phase III clinical trials showed an 86 percent efficacy rate, a 99 percent seroconversion rate of neutralizing antibody and 100 percent effectiveness in preventing moderate and severe cases of COVID-19, following testing on 42,299 volunteers, said the report.
Bahrain, which has participated in Phase III clinical trials of the vaccine in August, authorized the emergency use of Sinopharm s vaccine in November to cover those frontline professionals in contact with COVID-19 patients.
Bahrain approves China s Sinopharm vaccine for use
Sunday, the National Health Regulatory Authority (NHRA) in Bahrain announced the approval of the registration of the Sinopharm coronavirus vaccine, developed by China National Pharmaceutical Group.
“Results from Phase III clinical trials showed an 86 percent efficacy rate, a 99 percent seroconversion rate of neutralizing antibody and 100 percent effectiveness in preventing moderate and severe cases of COVID-19, the NHRA said in a statement. The vaccine has been tested on 42,299 volunteers.
Bahrain participated in phase III clinical trials of the vaccine as part of the 4 Humanity campaign, in which more than 7,700 volunteers signed up.
Bahrain approves registration for China s Sinopharm COVID-19 vaccine koreatimes.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreatimes.co.kr Daily Mail and Mail on Sunday newspapers.